O	0	11	Therapeutic	Therapeutic	JJ	B-NP
O	12	27	Electromagnetic	Electromagnetic	JJ	I-NP
O	28	33	Field	Field	NN	I-NP
O	34	35	(	(	(	O
O	35	39	TEMF	TEMF	NN	B-NP
O	39	40	)	)	)	O
O	41	44	and	and	CC	O
O	45	50	gamma	gamma	NN	B-NP
O	51	62	irradiation	irradiation	NN	I-NP
O	63	65	on	on	IN	B-PP
O	66	71	human	human	JJ	B-NP
B-Cancer	72	78	breast	breast	NN	I-NP
I-Cancer	79	85	cancer	cancer	NN	I-NP
I-Cancer	86	95	xenograft	xenograft	NN	I-NP
O	96	102	growth	growth	NN	I-NP
O	102	103	,	,	,	O
O	104	116	angiogenesis	angiogenesis	NN	B-NP
O	117	120	and	and	CC	I-NP
O	121	131	metastasis	metastasis	NN	I-NP
O	131	132	.	.	.	O

O	133	143	BACKGROUND	BACKGROUND	NN	B-NP
O	143	144	:	:	:	O
O	145	148	The	The	DT	B-NP
O	149	156	effects	effect	NNS	I-NP
O	157	159	of	of	IN	B-PP
O	160	161	a	a	DT	B-NP
O	162	171	rectified	rectify	VBN	I-NP
O	172	176	semi	semi	AFX	I-NP
O	176	177	-	-	HYPH	I-NP
O	177	185	sinewave	sinewave	NN	I-NP
O	186	192	signal	signal	NN	I-NP
O	193	194	(	(	(	O
O	194	196	15	15	CD	B-NP
O	197	199	mT	mT	NN	I-NP
O	200	209	amplitude	amplitude	NN	I-NP
O	209	210	,	,	,	O
O	211	214	120	120	CD	B-NP
O	215	221	pulses	pulse	NNS	I-NP
O	222	225	per	per	IN	B-PP
O	226	232	second	second	NN	B-NP
O	232	233	,	,	,	O
O	234	237	EMF	EMF	NNP	B-NP
O	238	250	Therapeutics	Therapeutics	NNP	I-NP
O	250	251	,	,	,	O
O	252	255	Inc	Inc	NNP	B-NP
O	255	256	.	.	.	O
O	256	257	)	)	)	O
O	258	259	(	(	(	O
O	259	263	TEMF	TEMF	NN	B-NP
O	263	264	)	)	)	O
O	265	270	alone	alone	RB	B-ADVP
O	271	274	and	and	CC	O
O	275	277	in	in	IN	B-PP
O	278	289	combination	combination	NN	B-NP
O	290	294	with	with	IN	B-PP
O	295	300	gamma	gamma	SYM	B-NP
O	301	312	irradiation	irradiation	NN	I-NP
O	313	314	(	(	(	O
O	314	316	IR	IR	NN	B-NP
O	316	317	)	)	)	O
O	318	325	therapy	therapy	NN	B-NP
O	326	328	in	in	IN	B-PP
O	329	333	nude	nude	JJ	B-NP
O	334	338	mice	mouse	NNS	I-NP
O	339	346	bearing	bear	VBG	B-VP
O	347	348	a	a	DT	B-NP
O	349	354	human	human	JJ	I-NP
B-Cancer	355	358	MDA	MDA	NN	I-NP
I-Cancer	359	364	MB231	MB231	NN	I-NP
I-Cancer	365	371	breast	breast	NN	I-NP
I-Cancer	372	378	cancer	cancer	NN	I-NP
I-Cancer	379	388	xenograft	xenograft	NN	I-NP
O	389	393	were	be	VBD	B-VP
O	394	400	tested	test	VBN	I-VP
O	400	401	.	.	.	O

O	402	407	Green	Green	JJ	B-NP
O	408	420	fluorescence	fluorescence	NN	I-NP
O	421	428	protein	protein	NN	I-NP
O	429	440	transfected	transfecte	VBN	B-VP
B-Cell	441	447	cancer	cancer	NN	B-NP
I-Cell	448	453	cells	cell	NNS	I-NP
O	454	458	were	be	VBD	B-VP
O	459	467	injected	inject	VBN	I-VP
O	468	472	into	into	IN	B-PP
O	473	476	the	the	DT	B-NP
B-Tissue	477	484	mammary	mammary	JJ	I-NP
I-Tissue	485	488	fat	fat	JJ	I-NP
I-Tissue	489	492	pad	pad	NN	I-NP
O	493	495	of	of	IN	B-PP
O	496	501	young	young	JJ	B-NP
O	502	508	female	female	JJ	I-NP
O	509	513	mice	mouse	NNS	I-NP
O	513	514	.	.	.	O

O	515	518	Six	Six	CD	B-NP
O	519	524	weeks	week	NNS	I-NP
O	525	530	later	later	RB	B-ADVP
O	530	531	,	,	,	O
O	532	536	mice	mouse	NNS	B-NP
O	537	541	were	be	VBD	B-VP
O	542	550	randomly	randomly	RB	I-VP
O	551	558	divided	divide	VBN	I-VP
O	559	563	into	into	IN	B-PP
O	564	568	four	four	CD	B-NP
O	569	578	treatment	treatment	NN	I-NP
O	579	585	groups	group	NNS	I-NP
O	585	586	:	:	:	O
O	587	596	untreated	untreated	JJ	B-NP
O	597	605	controls	control	NNS	I-NP
O	605	606	;	;	:	O
O	607	609	10	10	CD	B-NP
O	610	616	minute	minute	JJ	I-NP
O	617	622	daily	daily	JJ	I-NP
O	623	627	TEMF	TEMF	NN	I-NP
O	627	628	;	;	:	O
O	629	632	200	200	CD	B-NP
O	633	636	cGy	cGy	NN	I-NP
O	637	639	of	of	IN	B-PP
O	640	642	IR	IR	NN	B-NP
O	643	648	every	every	DT	B-NP
O	649	654	other	other	JJ	I-NP
O	655	658	day	day	NN	I-NP
O	659	660	(	(	(	O
O	660	665	total	total	NN	B-NP
O	666	669	800	800	CD	I-NP
O	670	673	cGy	cGy	NN	I-NP
O	673	674	)	)	)	O
O	674	675	;	;	:	O
O	676	678	IR	IR	NN	B-NP
O	679	683	plus	plus	CC	O
O	684	689	daily	daily	JJ	B-NP
O	690	694	TEMF	TEMF	NN	I-NP
O	694	695	.	.	.	O

O	696	700	Some	Some	DT	B-NP
O	701	705	mice	mouse	NNS	I-NP
O	706	708	in	in	IN	B-PP
O	709	713	each	each	DT	B-NP
O	714	719	group	group	NN	I-NP
O	720	724	were	be	VBD	B-VP
O	725	735	euthanized	euthanize	VBN	I-VP
O	736	738	24	24	CD	B-NP
O	739	744	hours	hour	NNS	I-NP
O	745	750	after	after	IN	B-PP
O	751	754	the	the	DT	B-NP
O	755	758	end	end	NN	I-NP
O	759	761	of	of	IN	B-PP
O	762	764	IR	IR	NN	B-NP
O	764	765	.	.	.	O

O	766	770	TEMF	TEMF	NN	B-NP
O	771	780	treatment	treatment	NN	I-NP
O	781	790	continued	continue	VBD	B-VP
O	791	794	for	for	IN	B-PP
O	795	796	3	3	CD	B-NP
O	797	807	additional	additional	JJ	I-NP
O	808	813	weeks	week	NNS	I-NP
O	813	814	.	.	.	O

B-Cancer	815	820	Tumor	Tumor	NN	B-NP
I-Cancer	821	829	sections	section	NNS	I-NP
O	830	834	were	be	VBD	B-VP
O	835	842	stained	stain	VBN	I-VP
O	843	846	for	for	IN	B-PP
O	846	847	:	:	:	O
B-Cell	848	859	endothelial	endothelial	JJ	B-NP
I-Cell	860	865	cells	cell	NNS	I-NP
O	866	870	with	with	IN	B-PP
O	871	875	CD31	CD31	NN	B-NP
O	876	879	and	and	CC	O
O	880	883	PAS	PAS	NN	B-NP
O	884	886	or	or	CC	O
O	887	894	hypoxia	hypoxia	NN	B-NP
O	895	904	inducible	inducible	JJ	I-NP
O	905	911	factor	factor	NN	I-NP
O	912	918	1alpha	1alpha	NN	I-NP
O	919	920	(	(	(	O
O	920	923	HIF	HIF	NN	B-NP
O	923	924	)	)	)	O
O	924	925	.	.	.	O

O	926	933	RESULTS	RESULTS	NNS	B-NP
O	933	934	:	:	:	O
O	935	939	Most	Most	JJS	B-NP
B-Cancer	940	946	tumors	tumor	NNS	I-NP
O	948	952	less	less	JJR	B-NP
O	953	957	than	than	IN	I-NP
O	958	960	35	35	CD	I-NP
O	961	964	mm3	mm3	NN	I-NP
O	965	969	were	be	VBD	B-VP
O	970	975	white	white	JJ	B-ADJP
O	976	979	but	but	CC	O
B-Cancer	980	986	tumors	tumor	NNS	B-NP
O	988	995	greater	great	JJR	B-ADJP
O	996	1000	than	than	IN	B-PP
O	1001	1003	35	35	CD	B-NP
O	1004	1007	mm3	mm3	NN	I-NP
O	1008	1012	were	be	VBD	B-VP
O	1013	1017	pink	pink	JJ	B-ADJP
O	1018	1021	and	and	CC	O
O	1022	1025	had	have	VBD	B-VP
O	1026	1027	a	a	DT	B-NP
O	1028	1040	vascularized	vascularize	VBN	I-NP
B-Cancer	1041	1048	capsule	capsule	NN	I-NP
O	1048	1049	.	.	.	O

O	1050	1053	The	The	DT	B-NP
B-Cancer	1054	1060	cortex	cortex	NN	I-NP
O	1061	1067	within	within	IN	B-PP
O	1068	1071	100	100	CD	B-NP
O	1072	1079	microns	micron	NNS	I-NP
O	1080	1082	of	of	IN	B-PP
O	1083	1086	the	the	DT	B-NP
B-Cancer	1087	1094	capsule	capsule	NN	I-NP
O	1095	1098	had	have	VBD	B-VP
O	1099	1105	little	little	JJ	B-NP
O	1106	1121	vascularization	vascularization	NN	I-NP
O	1121	1122	.	.	.	O

B-Multi-tissue_structure	1123	1128	Blood	Blood	NN	B-NP
I-Multi-tissue_structure	1129	1136	vessels	vessel	NNS	I-NP
O	1136	1137	,	,	,	O
B-Tissue	1138	1149	capillaries	capillary	NNS	B-NP
O	1149	1150	,	,	,	O
O	1151	1154	and	and	CC	O
B-Cellular_component	1155	1166	endothelial	endothelial	JJ	B-NP
I-Cellular_component	1167	1177	pseudopods	pseudopod	NNS	I-NP
O	1178	1182	were	be	VBD	B-VP
O	1183	1188	found	find	VBN	I-VP
O	1189	1191	at	at	IN	B-PP
O	1193	1200	greater	great	JJR	B-NP
O	1201	1205	than	than	IN	I-NP
O	1206	1209	100	100	CD	I-NP
O	1210	1217	microns	micron	NNS	I-NP
O	1218	1222	from	from	IN	B-PP
O	1223	1226	the	the	DT	B-NP
B-Cancer	1227	1234	capsule	capsule	NN	I-NP
O	1235	1236	(	(	(	O
B-Cancer	1236	1245	subcortex	subcortex	NN	B-NP
O	1245	1246	)	)	)	O
O	1246	1247	.	.	.	O

B-Cancer	1248	1254	Tumors	Tumor	NNS	B-NP
O	1256	1263	greater	great	JJR	B-ADJP
O	1264	1268	than	than	IN	B-PP
O	1269	1271	35	35	CD	B-NP
O	1272	1275	mm3	mm3	NN	I-NP
O	1276	1283	treated	treat	VBN	B-VP
O	1284	1288	with	with	IN	B-PP
O	1289	1291	IR	IR	NN	B-NP
O	1292	1294	24	24	CD	B-NP
O	1295	1300	hours	hour	NNS	I-NP
O	1301	1311	previously	previously	RB	B-ADVP
O	1312	1314	or	or	CC	O
O	1315	1319	with	with	IN	B-PP
O	1320	1324	TEMF	TEMF	NN	B-NP
O	1325	1328	had	have	VBD	B-VP
O	1329	1338	decreased	decrease	VBN	I-VP
B-Multi-tissue_structure	1339	1344	blood	blood	NN	B-NP
I-Multi-tissue_structure	1345	1352	vessels	vessel	NNS	I-NP
O	1353	1355	in	in	IN	B-PP
O	1356	1359	the	the	DT	B-NP
B-Cancer	1360	1369	subcortex	subcortex	NN	I-NP
O	1370	1373	and	and	CC	O
O	1374	1378	more	more	RBR	B-NP
B-Cellular_component	1379	1390	endothelial	endothelial	JJ	I-NP
I-Cellular_component	1391	1401	pseudopods	pseudopod	NNS	I-NP
O	1402	1412	projecting	project	VBG	B-VP
O	1413	1417	into	into	IN	B-PP
O	1418	1425	hypoxic	hypoxic	JJ	B-NP
O	1425	1426	,	,	,	I-NP
O	1427	1430	HIF	HIF	NN	I-NP
O	1431	1439	positive	positive	JJ	I-NP
O	1440	1445	areas	area	NNS	I-NP
O	1446	1450	than	than	IN	B-PP
B-Cancer	1451	1457	tumors	tumor	NNS	B-NP
O	1458	1462	from	from	IN	B-PP
O	1463	1466	the	the	DT	B-NP
O	1467	1474	control	control	NN	I-NP
O	1475	1480	group	group	NN	I-NP
O	1480	1481	.	.	.	O

O	1482	1486	Mice	Mouse	NNS	B-NP
O	1487	1491	that	that	WDT	B-NP
O	1492	1500	received	receive	VBD	B-VP
O	1501	1507	either	either	CC	O
O	1508	1510	IR	IR	NN	B-NP
O	1511	1513	or	or	CC	I-NP
O	1514	1518	TEMF	TEMF	NN	I-NP
O	1519	1522	had	have	VBD	B-VP
O	1523	1536	significantly	significantly	RB	B-NP
O	1537	1542	fewer	few	JJR	I-NP
B-Cancer	1543	1547	lung	lung	NN	I-NP
I-Cancer	1548	1558	metastatic	metastatic	JJ	I-NP
I-Cancer	1559	1564	sites	site	NNS	I-NP
O	1565	1568	and	and	CC	O
O	1569	1575	slower	slow	JJR	B-NP
B-Cancer	1576	1581	tumor	tumor	NN	I-NP
O	1582	1588	growth	growth	NN	I-NP
O	1589	1593	than	than	IN	B-SBAR
O	1594	1597	did	do	VBD	O
O	1598	1607	untreated	untreated	JJ	B-NP
O	1608	1612	mice	mouse	NNS	I-NP
O	1612	1613	.	.	.	O

O	1614	1616	No	No	DT	B-NP
O	1617	1624	harmful	harmful	JJ	I-NP
O	1625	1629	side	side	NN	I-NP
O	1630	1637	effects	effect	NNS	I-NP
O	1638	1642	were	be	VBD	B-VP
O	1643	1653	attributed	attribute	VBN	I-VP
O	1654	1656	to	to	TO	B-PP
O	1657	1661	TEMF	TEMF	NN	B-NP
O	1661	1662	.	.	.	O

O	1663	1673	CONCLUSION	CONCLUSION	NN	B-NP
O	1673	1674	:	:	:	O
O	1675	1679	TEMF	TEMF	NN	B-NP
O	1680	1687	therapy	therapy	NN	I-NP
O	1688	1696	provided	provide	VBD	B-VP
O	1697	1698	a	a	DT	B-NP
O	1699	1703	safe	safe	JJ	I-NP
O	1704	1709	means	mean	NNS	I-NP
O	1710	1713	for	for	IN	B-PP
O	1714	1723	retarding	retard	VBG	B-VP
B-Cancer	1724	1729	tumor	tumor	NN	B-NP
O	1730	1745	vascularization	vascularization	NN	I-NP
O	1745	1746	,	,	,	O
O	1747	1753	growth	growth	NN	B-NP
O	1754	1757	and	and	CC	I-NP
O	1758	1768	metastasis	metastasis	NN	I-NP
O	1768	1769	.	.	.	O

